Skip to main content
Clinical Trials/NCT02023775
NCT02023775
Completed
N/A

Non Interventional Study on Pulmonary Valve Replacement by Thranscatheter Pulmonary Valve Melody™

Medtronic Cardiac Rhythm and Heart Failure10 sites in 1 country409 target enrollmentJanuary 31, 2010

Overview

Phase
N/A
Intervention
Not specified
Conditions
Right Ventricular Congenital Cardiopathies
Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Enrollment
409
Locations
10
Primary Endpoint
absence of re-intervention on the pulmonary valve
Status
Completed
Last Updated
10 months ago

Overview

Brief Summary

Prospective, longitudinal, open-label, multicentre, observational, non-comparative national study using an exhaustive registry of implantations over a given period.

This study is requested by French Health Authorities for reimbursement renewal, to maintain reimbursement for pulmonary valvular replacement by bioprothesis in approved indication in France.

Detailed Description

This is a prospective, longitudinal, open-label, multicentre, observational, non-comparative national study using an exhaustive registry of implantations over a given period in France. The study is requested by French Health Authorities in 2010 for reimbursement renewal, to maintain reimbursement for pulmonary valvular replacement by bioprothesis in approved indication in France. The study was closed in 2013.

Registry
clinicaltrials.gov
Start Date
January 31, 2010
End Date
October 20, 2013
Last Updated
10 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients requiring pulmonary valvular replacement for correction of right ventricular ejection path malfunction (stenosis and/or pulmonary regurgitation).

Exclusion Criteria

  • Patient or legal representative refusal to data collection or processing
  • Patient unable to guarantee follow-up data collection, in particular for patients living abroad

Outcomes

Primary Outcomes

absence of re-intervention on the pulmonary valve

Time Frame: 12 months

to evaluate the efficacy of the MELODY valve, defined as the absence of re-intervention on the pulmonary valvee

Secondary Outcomes

  • rate re-intervention on the valve(60 months)
  • patient characteristics(60 months)
  • survival rate at 12, 36, 48 and 60 months(60 months)
  • frequency of antiplatelet treatment during and after implant(60 months)
  • Description and time of onset of open surgery after implantation(60 months)
  • failures of the implantation procedure(60 months)
  • patients' characteristics to indications of the MELODY™ bioprosthesis(60 months)
  • time period before the resumption of professional, university or scholastic activity(60 months)
  • time period before re-intervention on the valve(60 months)

Study Sites (10)

Loading locations...

Similar Trials